Literature DB >> 29632166

BACE1 Mediates HIV-Associated and Excitotoxic Neuronal Damage Through an APP-Dependent Mechanism.

Anna L Stern1, Shivesh Ghura1, Patrick J Gannon1, Cagla Akay-Espinoza1, Jessica M Phan1, Alan C Yee1, Robert Vassar2, Benjamin B Gelman3, Dennis L Kolson4, Kelly L Jordan-Sciutto5.   

Abstract

HIV-associated neurocognitive disorders (HANDs) share common symptoms with Alzheimer's disease (AD), which is characterized by amyloid-β (Aβ) plaques. Plaques are formed by aggregation of Aβ oligomers, which may be the toxic species in AD pathogenesis, and oligomers are generated by cleavage of amyloid precursor protein (APP) by β-site amyloid precursor protein cleaving enzyme 1 (BACE1). BACE1 inhibitors reverse neuronal loss and cognitive decline in animal models of AD. Although studies have also found evidence of altered APP processing in HIV+ patients, it is unknown whether increased BACE1 expression or Aβ oligomer production is a common neuropathological feature of HAND. Moreover, it is unknown whether BACE1 or APP is involved in the excitotoxic, NMDAR-dependent component of HIV-associated neurotoxicity in vitro Herein, we hypothesize that HIV-associated neurotoxicity is mediated by NMDAR-dependent elevation of BACE1 and subsequent altered processing of APP. Supporting this, we observed elevated levels of BACE1 and Aβ oligomers in CNS of male and female HIV+ patients. In a model of HIV-associated neurotoxicity in which rat neurons are treated with supernatants from HIV-infected human monocyte-derived macrophages, we observed NMDAR-dependent elevation of BACE1 protein. NMDA treatment also increased BACE1 and both pharmacological BACE1 inhibition and genetic loss of APP were partially neuroprotective. Moreover, in APP knock-out (APP-/-) mouse neurons, NMDA-induced toxicity was BACE1 independent, indicating that cytotoxicity of BACE1 is dependent upon APP cleavage. Our findings suggest that increased BACE1 and the resultant Aβ oligomer production may contribute to HIV-associated neuropathogenesis and inhibition of BACE1 could have therapeutic potential in HANDs.SIGNIFICANCE STATEMENT HIV-associated neurocognitive disorders (HANDs) represent a range of cognitive impairments affecting ∼50% of HIV+ individuals. The specific causes of HAND are unknown, but evidence suggests that HIV-infected macrophage infiltration into the brain may cause neuronal damage. Herein, we show that neurons treated with conditioned media from HIV-infected macrophages have increased expression of β-site amyloid precursor protein cleaving enzyme 1 (BACE1), a protein implicated in Alzheimer's disease pathogenesis. Moreover, inhibition of BACE1 prevented neuronal loss after conditioned media exposure, but had no effect on HIV-associated neurotoxicity in neurons lacking its cleavage target amyloid precursor protein. We also observed increased BACE1 expression in HIV+ patient brain tissue, confirming the potential relevance of BACE1 as a therapeutic target in HANDs.
Copyright © 2018 the authors 0270-6474/18/384288-13$15.00/0.

Entities:  

Keywords:  APP; Alzheimer's disease; BACE1; HIV-associated neurocognitive disorders; NMDA; excitotoxicity

Mesh:

Substances:

Year:  2018        PMID: 29632166      PMCID: PMC5932640          DOI: 10.1523/JNEUROSCI.1280-17.2018

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  83 in total

1.  Subtype selective NMDA receptor antagonists induce recovery of synapses lost following exposure to HIV-1 Tat.

Authors:  A H Shin; H J Kim; S A Thayer
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739

2.  Calpain inhibitor MDL28170 modulates Abeta formation by inhibiting the formation of intermediate Abeta46 and protecting Abeta from degradation.

Authors:  Yunzhou Dong; Jianxin Tan; Mei-Zhen Cui; Guojun Zhao; Guozhang Mao; Neena Singh; Xuemin Xu
Journal:  FASEB J       Date:  2005-12-14       Impact factor: 5.191

3.  Elevated glutamate in the cerebrospinal fluid of patients with HIV dementia.

Authors:  C Ferrarese; R Riva; A Dolara; A De Micheli; L Frattola
Journal:  JAMA       Date:  1997-02-26       Impact factor: 56.272

4.  CSF amyloid beta42 and tau levels correlate with AIDS dementia complex.

Authors:  B J Brew; L Pemberton; K Blennow; A Wallin; L Hagberg
Journal:  Neurology       Date:  2005-11-08       Impact factor: 9.910

5.  Gp120 can revert antagonism at the glycine site of NMDA receptors mediating GABA release from cultured hippocampal neurons.

Authors:  G Fontana; L Valenti; M Raiteri
Journal:  J Neurosci Res       Date:  1997-09-15       Impact factor: 4.164

6.  Secretion of neurotoxins by mononuclear phagocytes infected with HIV-1.

Authors:  D Giulian; K Vaca; C A Noonan
Journal:  Science       Date:  1990-12-14       Impact factor: 47.728

7.  Brain deposition of beta-amyloid is a common pathologic feature in HIV positive patients.

Authors:  Douglas A Green; Eliezer Masliah; Harry V Vinters; Pouneh Beizai; David J Moore; Cristian L Achim
Journal:  AIDS       Date:  2005-03-04       Impact factor: 4.177

8.  Endolysosome involvement in HIV-1 transactivator protein-induced neuronal amyloid beta production.

Authors:  Xuesong Chen; Liang Hui; Nicholas H Geiger; Norman J Haughey; Jonathan D Geiger
Journal:  Neurobiol Aging       Date:  2013-05-11       Impact factor: 4.673

Review 9.  Neuropathology of HAND With Suppressive Antiretroviral Therapy: Encephalitis and Neurodegeneration Reconsidered.

Authors:  Benjamin B Gelman
Journal:  Curr HIV/AIDS Rep       Date:  2015-06       Impact factor: 5.071

Review 10.  Role of NMDA Receptor-Mediated Glutamatergic Signaling in Chronic and Acute Neuropathologies.

Authors:  Francisco J Carvajal; Hayley A Mattison; Waldo Cerpa
Journal:  Neural Plast       Date:  2016-08-18       Impact factor: 3.599

View more
  19 in total

1.  The current understanding of overlap between characteristics of HIV-associated neurocognitive disorders and Alzheimer's disease.

Authors:  Leah H Rubin; Erin E Sundermann; David J Moore
Journal:  J Neurovirol       Date:  2019-01-22       Impact factor: 2.643

Review 2.  White matter loss and oligodendrocyte dysfunction in HIV: A consequence of the infection, the antiretroviral therapy or both?

Authors:  Brigid K Jensen; Lindsay M Roth; Judith B Grinspan; Kelly L Jordan-Sciutto
Journal:  Brain Res       Date:  2019-08-20       Impact factor: 3.252

Review 3.  The Integrated Stress Response and Phosphorylated Eukaryotic Initiation Factor 2α in Neurodegeneration.

Authors:  Sarah Bond; Claudia Lopez-Lloreda; Patrick J Gannon; Cagla Akay-Espinoza; Kelly L Jordan-Sciutto
Journal:  J Neuropathol Exp Neurol       Date:  2020-02-01       Impact factor: 3.685

4.  Protease Inhibitors, Saquinavir and Darunavir, Inhibit Oligodendrocyte Maturation: Implications for Lysosomal Stress.

Authors:  Lindsay Festa; Lindsay M Roth; Brigid K Jensen; Jonathan D Geiger; Kelly L Jordan-Sciutto; Judith B Grinspan
Journal:  J Neuroimmune Pharmacol       Date:  2019-11-28       Impact factor: 4.147

Review 5.  Mechanisms of neuronal dysfunction in HIV-associated neurocognitive disorders.

Authors:  Elena Irollo; Jared Luchetta; Chunta Ho; Bradley Nash; Olimpia Meucci
Journal:  Cell Mol Life Sci       Date:  2021-02-13       Impact factor: 9.261

6.  HIV-induced neuroinflammation inhibits oligodendrocyte maturation via glutamate-dependent activation of the PERK arm of the integrated stress response.

Authors:  Lindsay M Roth; Cagla Akay-Espinoza; Judith B Grinspan; Kelly L Jordan-Sciutto
Journal:  Glia       Date:  2021-05-31       Impact factor: 8.073

7.  HIV-1 Tat-mediated astrocytic amyloidosis involves the HIF-1α/lncRNA BACE1-AS axis.

Authors:  Susmita Sil; Guoku Hu; Ke Liao; Fang Niu; Shannon Callen; Palsamy Periyasamy; Howard S Fox; Shilpa Buch
Journal:  PLoS Biol       Date:  2020-05-26       Impact factor: 8.029

Review 8.  Beneficial and Adverse Effects of cART Affect Neurocognitive Function in HIV-1 Infection: Balancing Viral Suppression against Neuronal Stress and Injury.

Authors:  Nina Y Yuan; Marcus Kaul
Journal:  J Neuroimmune Pharmacol       Date:  2019-08-06       Impact factor: 4.147

Review 9.  Environmental exposures and the etiopathogenesis of Alzheimer's disease: The potential role of BACE1 as a critical neurotoxic target.

Authors:  Tauqeerunnisa Syeda; Jason R Cannon
Journal:  J Biochem Mol Toxicol       Date:  2021-01-04       Impact factor: 3.642

10.  Small molecule modulation of the p75 neurotrophin receptor suppresses age- and genotype-associated neurodegeneration in HIV gp120 transgenic mice.

Authors:  Youmie Xie; Jaimie Seawell; Emily Boesch; Lauren Allen; Ashley Suchy; Frank M Longo; Rick B Meeker
Journal:  Exp Neurol       Date:  2020-09-29       Impact factor: 5.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.